ATE533502T1 - Verfahren zur modulation der il-23-aktivität; relevante reagenzien - Google Patents

Verfahren zur modulation der il-23-aktivität; relevante reagenzien

Info

Publication number
ATE533502T1
ATE533502T1 AT05713576T AT05713576T ATE533502T1 AT E533502 T1 ATE533502 T1 AT E533502T1 AT 05713576 T AT05713576 T AT 05713576T AT 05713576 T AT05713576 T AT 05713576T AT E533502 T1 ATE533502 T1 AT E533502T1
Authority
AT
Austria
Prior art keywords
modulating
activity
relevant reagents
reagents
relevant
Prior art date
Application number
AT05713576T
Other languages
English (en)
Inventor
Peter D Katsikis
Ioannis Dimitriou
Daniel J Cua
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE533502T1 publication Critical patent/ATE533502T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276Knock-out vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/208IL-12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869Interleukin
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00Modified animals
    • A01K2207/20Animals treated with compounds which are neither proteins nor nucleic acids
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/054Animals comprising random inserted nucleic acids (transgenic) inducing loss of function
    • A01K2217/056Animals comprising random inserted nucleic acids (transgenic) inducing loss of function due to mutation of coding region of the transgene (dominant negative)
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0337Animal models for infectious diseases
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/11Orthomyxoviridae, e.g. influenza virus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/26Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Environmental Sciences (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biophysics (AREA)
AT05713576T 2004-02-17 2005-02-15 Verfahren zur modulation der il-23-aktivität; relevante reagenzien ATE533502T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54570804P 2004-02-17 2004-02-17
PCT/US2005/004742 WO2005079837A1 (en) 2004-02-17 2005-02-15 Methods of modulating il-23 activity; related reagents

Publications (1)

Publication Number Publication Date
ATE533502T1 true ATE533502T1 (de) 2011-12-15

Family

ID=34886185

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05713576T ATE533502T1 (de) 2004-02-17 2005-02-15 Verfahren zur modulation der il-23-aktivität; relevante reagenzien

Country Status (12)

Country Link
US (1) US8263080B2 (de)
EP (1) EP1901768B1 (de)
JP (2) JP4903061B2 (de)
CN (1) CN1942201B (de)
AT (1) ATE533502T1 (de)
AU (1) AU2005215527B2 (de)
BR (1) BRPI0507794A (de)
CA (1) CA2556425A1 (de)
NO (1) NO20064194L (de)
NZ (1) NZ548897A (de)
WO (1) WO2005079837A1 (de)
ZA (1) ZA200606620B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CN1711282B (zh) * 2002-10-30 2010-05-26 健泰科生物技术公司 Il-17产生的抑制
HUE042561T2 (hu) 2005-06-30 2019-07-29 Janssen Biotech Inc Anti-IL-23-ellenanyagok, készítmények, eljárások és alkalmazások
US7872102B2 (en) * 2005-08-25 2011-01-18 Eli Lilly And Company Anti-IL-23 antibodies
RS53685B1 (en) 2005-12-29 2015-04-30 Janssen Biotech Inc. HUMAN ANTI-IL-23 ANTIBODIES, COMPOSITIONS, METHODS AND APPLICATIONS
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
JP2009540018A (ja) * 2006-06-13 2009-11-19 ザイモジェネティクス, インコーポレイテッド Il−17およびil−23アンタゴニストならびにその使用方法
TWI426918B (zh) * 2007-02-12 2014-02-21 Merck Sharp & Dohme Il-23拮抗劑於治療感染之用途
MX2009009283A (es) * 2007-02-28 2009-11-18 Schering Corp Anticuerpos anti-interleuquina -23r de ingenieria.
AU2008328784B2 (en) 2007-11-27 2014-03-27 Ablynx N.V. Immunoglobulin constructs
KR20150002874A (ko) 2008-05-05 2015-01-07 노비뮨 에스 에이 항-il-17a/il-17f 교차-반응성 항체 및 그의 사용 방법
CN102458437B (zh) 2009-05-05 2015-06-10 诺维莫尼公司 抗il-17f抗体及其使用方法
WO2011033493A1 (en) * 2009-09-21 2011-03-24 Conservatoire National des Arts et Métiers Carrier conjugates of il-23-peptides and their induced antibodies
CA2816950C (en) 2010-11-04 2018-11-27 Boehringer Ingelheim International Gmbh Anti-il-23 antibodies
EA201401204A1 (ru) 2012-05-03 2015-05-29 Бёрингер Ингельхайм Интернациональ Гмбх Антитела к il-23p19
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
CN103837687A (zh) * 2014-03-10 2014-06-04 青岛康立泰药业有限公司 使用具有白细胞介素-12受体的细胞检测重组人白细胞介素-12体外活性的方法及应用
EP3708679A1 (de) 2014-07-24 2020-09-16 Boehringer Ingelheim International GmbH In der behandlung von il-23a-assoziierten erkrankungen nützlicher biomarker
PE20171139A1 (es) 2014-09-03 2017-08-09 Boehringer Ingelheim Int Compuesto dirigido a il-23a y tnf-alfa y sus usos
KR101873499B1 (ko) * 2015-02-10 2018-07-03 주식회사 원메디칼 혈관 질환 진단용 바이오 마커 및 이의 용도
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3618871A4 (de) 2017-05-02 2021-01-06 Merck Sharp & Dohme Corp. Formulierungen von anti-lag3-antikörpern und co-formulierungen von anti-lag3-antikörpern und anti-pd-1-antikörpern
WO2018218231A1 (en) * 2017-05-25 2018-11-29 The Broad Institute, Inc. Lymphocyte antigen cd5like (cd5l) monomer, homodimer, and interleukin 12b (p40) heterodimer antagonists and methods of use thereof
US20200147177A1 (en) * 2017-07-17 2020-05-14 Chu De Nantes - Centre Hospitalier Universitaire De Nantes Interleukin 12 (il12) or derivative thereof for use in the treatment of secondary disease
AU2019383017A1 (en) 2018-11-20 2021-06-03 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
MX2021014302A (es) 2019-05-23 2022-01-04 Janssen Biotech Inc Metodo para tratar la enfermedad inflamatoria del intestino con una terapia de combinacion de anticuerpos contra il-23 y tnf alfa.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6326482B1 (en) 1999-04-23 2001-12-04 Genentech, Inc. SH2 domain-containing peptides
EP2275548A1 (de) * 2000-05-10 2011-01-19 Schering Corporation Zytokinrezeptoruntereinheit-Proteine aus Säugetieren, damit zusammenhängende Reagenzien und Methoden
US7422743B2 (en) * 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
US6902734B2 (en) * 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
AU2003243189B2 (en) * 2002-05-01 2008-01-24 Regeneron Pharmaceuticals, Inc. Methods of using cytokine antagonists to treat HIV infection and AIDS
CN1711282B (zh) * 2002-10-30 2010-05-26 健泰科生物技术公司 Il-17产生的抑制
ES2367302T3 (es) * 2002-12-23 2011-11-02 Schering Corporation Usos de la citoquina il-23 de mamífero; reactivos relacionados.
US7445779B2 (en) * 2002-12-31 2008-11-04 Schering Corporation Methods of modulating IFNy production
US20040219150A1 (en) * 2003-02-06 2004-11-04 Cua Daniel J. Uses of mammalian cytokine; related reagents
PL1601694T3 (pl) * 2003-03-10 2010-02-26 Merck Sharp & Dohme Zastosowania antagonistów IL-23; pokrewne reagenty
US7582297B2 (en) * 2003-04-11 2009-09-01 Medimmune, Llc Methods of treating respiratory conditions
JP2007515939A (ja) * 2003-05-09 2007-06-21 セントカー・インコーポレーテツド IL−23p40特異的免疫グロブリン由来タンパク質、組成物、方法および用途

Also Published As

Publication number Publication date
WO2005079837A1 (en) 2005-09-01
EP1901768A1 (de) 2008-03-26
US8263080B2 (en) 2012-09-11
AU2005215527A1 (en) 2005-09-01
EP1901768B1 (de) 2011-11-16
CN1942201B (zh) 2012-06-20
AU2005215527B2 (en) 2011-04-07
NZ548897A (en) 2009-07-31
US20050208052A1 (en) 2005-09-22
ZA200606620B (en) 2008-02-27
NO20064194L (no) 2006-11-16
BRPI0507794A (pt) 2007-07-17
JP4903061B2 (ja) 2012-03-21
CA2556425A1 (en) 2005-09-01
JP2012092117A (ja) 2012-05-17
JP2007523088A (ja) 2007-08-16
CN1942201A (zh) 2007-04-04

Similar Documents

Publication Publication Date Title
ATE533502T1 (de) Verfahren zur modulation der il-23-aktivität; relevante reagenzien
ATE504836T1 (de) Verfahren zur identifizierung von trpv2- modulatoren
DE602005019156D1 (de) Verfahren zur auswertung von ribonukleotidsequenzen
ATE435209T1 (de) Verfahren zur herstellung von montelukast-natrium
DE602006013390D1 (de) Drahtloses Kommunikationssystem, Kommunikationsvorrichtung, Verfahren zur Bereitstellung und zum Erhalten von Einstellungsinformationen und Computerprogramm.
DE602005010649D1 (de) Server, Serversystem und Verfahren zur Zustellung von E-mails
DE602005025187D1 (de) Dienstleistungssystem, Dienstleistungsserver und Verfahren zur Authentifizierung von Dienstanforderungen
NO20064193L (no) fremgangsmate for a modulere cytokinaktivitet, beslektede reagenser
ATE428282T1 (de) Verfahren und vorrichtung der drahtlosen kommunikation zur optimierung der leistungsfahigkeit von zugangspunkten
ATE481092T1 (de) Verfahren und zusammensetzungen zur apoptoseinduktion in krebszellen
DE602005003176D1 (de) Verfahren und Vorrichtung zur Datenübertragung unter Verwendung der Zusammensetzung von Paketen
DE602005021336D1 (de) Verfahren zur identifizierung von proteinen mit stärkephosphorylierender enzymatischer aktivität
DE602005023068D1 (de) Verfahren und system zur zuweisung von kommunikationsressourcen
TW200531679A (en) Methods of modulating cytokine activity; related reagents
DE602006008098D1 (de) Verfahren und System zur Verwaltung von Datenverkehr
BRPI0606370A2 (pt) tratamento dos distúrbios de hcv
DE602004032465D1 (de) Referenzstandard zur charakterisierung von rosuvastatin
BRPI0612209B8 (pt) método para preparar uma mídia de impressão e mídia de impressão
DE602006003047D1 (de) Vorrichtung und Verfahren zur Übertragung von Paketen im Drahtlosnetzwerk
ATE479778T1 (de) Verfahren zur diagnose nicht-kleinzelliger lungenkarzinome über die trna-dihydrouridin- synthaseaktivität von urlc8
ATE478156T1 (de) Verfahren zur identifizierung von modulatoren der eoxin-bildung
DE602006010187D1 (de) Einzelsequenzhybridisierungssonden
DE602005003906D1 (de) System und Verfahren zur Bereitstellung von differenzierten Dienstqualitäten
ATE543429T1 (de) Verfahren zur bestimmung des sympathikus-tonus und messsystem dafür
ATE551605T1 (de) Verfahren und vorrichtungen zur erkennung von biofilmen